PsyLabs

Psyence Group Announces Closing of Previously Announced Disposal of its Stake in PsyLabs

2024-11-07T09:16:20+02:00November 7, 2024|Press Releases, Investor Information, Psychedelic News|

Per the terms of the Disposal, Psyence Biomed will issue to Psyence Group 2,000,000 shares of its common stock. PsyLabs is focused on the cultivation and production of psychedelic active pharmaceutical ingredients (APIs) and extracts for use in research, clinical trials and drug development.

Psyence Group Enters into Agreement to Dispose of Stake in PsyLabs

2024-10-29T13:47:02+02:00September 20, 2024|Press Releases, Investor Information, Psychedelic News|

Psyence Group Inc ("Psyence Group" or the "Company") (CSE: PSYG) (as seller), a life science biotechnology company pioneering the use of nature-derived psilocybin in mental health and wellbeing, today announced that it has entered into a conditional share sale agreement with its NASDAQ-listed associate, Psyence Biomedical Ltd. (Nasdaq: PBM) ("Psyence Biomed" or "PBM") (as purchaser) for the disposal by Psyence Group of its 11.13% stake in privately-held PsyLabs, a company focused on the production of psychedelic active pharmaceutical ingredients (APIs) and extracts for use in research, clinical trials and drug development ("Proposed Transaction"). Per the terms of the Proposed Transaction,

Go to Top